公开(公告)号：US20230322867A1

公开(公告)日：2023-10-12

申请号：US18006689

申请日：2021-07-22

Applicant: AMGEN INC.

Inventor： Fernando GARCES ,  Zhulun WANG ,  Timothy RILEY

IPC: C07K14/165 ,  C12N15/85 ,  C07K16/10

CPC classification number: C07K14/165 ,  C07K16/10 ,  C12N15/85 ,  A61K2039/505

Abstract: The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.

公开(公告)号：US20240002545A1

公开(公告)日：2024-01-04

申请号：US18252442

申请日：2021-11-09

Applicant: AMGEN INC.

Inventor： Timothy RILEY ,  Fernando GARCES ,  Zhulun WANG ,  Bram Estes ,  Darren L. Bates

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/31

Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.